Tonix Pharmaceuticals Holding logo

Tonix Pharmaceuticals HoldingNASDAQ: TNXP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 May 2012

Next earnings report:

01 April 2025

Last dividends:

N/A

Next dividends:

N/A
$45.60 M
-79%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector
-45%vs. 3y high
31%vs. sector
-34%vs. 3y high
55%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:59:49 GMT
$0.24+$0.11(+83.87%)

Dividend

No data over the past 3 years
$2.82 M$3.20 M
$2.82 M-$14.21 M

Analysts recommendations

Institutional Ownership

TNXP Latest News

Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual
globenewswire.com18 November 2024 Sentiment: POSITIVE

CHATHAM, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Winter 2024 Investor Summit Virtual on Thursday, November 21, 2024, at 10:00 a.m. ET.

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
accesswire.com14 November 2024 Sentiment: POSITIVE

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals
globenewswire.com13 November 2024 Sentiment: POSITIVE

The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Second Mpox-related WHO PHEIC declaration in two years

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
globenewswire.com01 November 2024 Sentiment: POSITIVE

New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix's attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference
globenewswire.com25 October 2024 Sentiment: POSITIVE

CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 30, 2024, at 9:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals
globenewswire.com08 October 2024 Sentiment: POSITIVE

AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures

The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions
accesswire.com01 October 2024 Sentiment: POSITIVE

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines
globenewswire.com27 September 2024 Sentiment: POSITIVE

New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No.

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines
globenewswire.com19 September 2024 Sentiment: POSITIVE

New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No.

New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
accesswire.com18 September 2024 Sentiment: POSITIVE

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

  • 1(current)
  • 2

What type of business is Tonix Pharmaceuticals Holding?

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

What sector is Tonix Pharmaceuticals Holding in?

Tonix Pharmaceuticals Holding is in the Healthcare sector

What industry is Tonix Pharmaceuticals Holding in?

Tonix Pharmaceuticals Holding is in the Biotechnology industry

What country is Tonix Pharmaceuticals Holding from?

Tonix Pharmaceuticals Holding is headquartered in United States

When did Tonix Pharmaceuticals Holding go public?

Tonix Pharmaceuticals Holding initial public offering (IPO) was on 10 May 2012

What is Tonix Pharmaceuticals Holding website?

https://www.tonixpharma.com

Is Tonix Pharmaceuticals Holding in the S&P 500?

No, Tonix Pharmaceuticals Holding is not included in the S&P 500 index

Is Tonix Pharmaceuticals Holding in the NASDAQ 100?

No, Tonix Pharmaceuticals Holding is not included in the NASDAQ 100 index

Is Tonix Pharmaceuticals Holding in the Dow Jones?

No, Tonix Pharmaceuticals Holding is not included in the Dow Jones index

When was Tonix Pharmaceuticals Holding the previous earnings report?

No data

When does Tonix Pharmaceuticals Holding earnings report?

The next expected earnings date for Tonix Pharmaceuticals Holding is 01 April 2025